Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.

http://www.wikidata.org/entity/Q34237413

about

Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease Alogliptin benzoate for management of type 2 diabetes Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus.Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials.Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.Alogliptin (nesina) for adults with type-2 diabetes.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation.Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes.Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Once weekly exenatide: efficacy, tolerability and place in therapy.Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.Alogliptin.Alogliptin: safety, efficacy, and clinical implications.Alogliptin benzoate for the treatment of type 2 diabetes.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.Pharmacologic treatment of type 2 diabetes: oral medications.Combination therapy when metformin is not an option for type 2 diabetes.Alogliptin: a review of its use in patients with type 2 diabetes mellitus.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes.Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.The power of two: an update on fixed-dose combinations for type 2 diabetes.What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?

P2860

Q24288949-33FCA1EE-155F-4D08-9824-7D8A0D872A24 Q26765047-85DE134D-5197-4D07-94AC-1EE22DAAC03C Q28069065-75F33FF8-2F1D-4525-B972-E606AA6788D8 Q28083933-E6A41E7D-F207-40C0-93F3-092A8A605FC1 Q28294225-6D95AE27-483F-4E41-8951-55D4D53C011D Q28732681-FBA2E2D2-0A92-4DFB-A6B2-BFE14CE593E0 Q30846870-DC8CA532-F916-4786-B677-AC75C53B8574 Q33785197-323BD367-3191-42DC-B46B-F7378CFF725E Q33874654-82977026-EC2F-4FB7-9F2A-E0BB3F515BFF Q35236019-19E6EB20-2CEE-4F5A-92F4-CDB3699740B5 Q35688028-887743A7-29A6-42E3-A90B-76A00CD1356A Q35717211-5AF23713-1D9E-49AF-9C3A-722767BAFA8A Q36706802-D390B3A5-5004-4761-99B9-40A682C17AAE Q37195882-A4EB99EF-FE22-4EE4-8A4D-B39832F0DFDA Q37343916-6A02A869-D1B9-4BF8-89CC-DF6FD8B91A66 Q37639487-E26907A4-3376-41A1-ABE3-B4732E21361D Q37733244-C70284EB-F3BB-4135-A295-2FAFAAF98932 Q37866299-A23AC1D9-3457-454E-B0E3-195FAA03B408 Q37910902-2E32ABEB-1C09-4DBD-BB7A-029ADCB8AA19 Q38024383-1DBBD5FE-BE99-4FE1-9167-F149D7994BEF Q38058568-08937631-9D43-4D67-A033-B14870DF732F Q38076330-AEA7749F-988C-4A71-95FE-7F98453634AC Q38083112-4FD5FA2A-3E7C-4CE0-99E4-EE6CFB8A456A Q38167010-0AA424DB-1D0E-40CB-9208-0F635C3CA4E7 Q38178240-72CB0D57-3B56-4C52-832D-21FD860B36D2 Q38188548-9B7C4069-1043-4736-B973-71F2E69D35D7 Q38197275-FCDE4143-E259-4BFD-8BC0-122A32E83A87 Q38219482-71E0A0E0-73B2-4D58-A034-693F4CB3F63C Q38350347-63B15D69-AD7E-466F-9C4D-9A93624A5B8F Q38377267-39EEB602-98CC-4449-B4A5-93843DFF8752 Q38412153-C7866102-2D50-4F72-8994-71803104561A Q38455771-5A577629-2BEB-426E-AC0D-1EDCD3998E27 Q38468017-7EAF50C5-8DEB-4343-BAE6-9D632F6998C1 Q38546981-ED0E4947-D34F-4760-AD6A-D0B1746A0822 Q38556037-C9086242-C003-498A-8AD4-E8A4D2FBEF27 Q38603506-BBAB6E72-D141-47F6-9212-EF14695A9F4E Q38762377-0640E838-2913-4CC1-8007-F884B3FF51F1 Q38778476-70053EDB-AC28-43FA-92B5-5991274331AB Q38920983-096C50DD-B5C1-4820-A5CE-E5BEEBE302F2 Q38931845-41BFCE8D-7BA8-4E22-9199-F85ED4DB3DEC

P2860

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.

http://www.wikidata.org/entity/Q34237413

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Initial combination therapy wi ...... patients with type 2 diabetes.

@ast

Initial combination therapy wi ...... patients with type 2 diabetes.

@en

Initial combination therapy wi ...... patients with type 2 diabetes.

@nl

type

label

Initial combination therapy wi ...... patients with type 2 diabetes.

@ast

Initial combination therapy wi ...... patients with type 2 diabetes.

@en

Initial combination therapy wi ...... patients with type 2 diabetes.

@nl

prefLabel

Initial combination therapy wi ...... patients with type 2 diabetes.

@ast

Initial combination therapy wi ...... patients with type 2 diabetes.

@en

Initial combination therapy wi ...... patients with type 2 diabetes.

@nl

P1433

Q34237413-2733C937-6B63-43F9-9B92-BA12C7E96BA9

P1476

Q34237413-CF59A1C6-CDEB-448D-8287-1E6D1A0E519C

P2093

Q34237413-00EF77E6-537D-4AF9-844A-A2822BC7CED0

Q34237413-3D546A58-5D1E-4877-BE7F-4CEADB65506E

Q34237413-72BBDE97-9696-4CB8-9050-E49A9034FE5B

Q34237413-A6A31976-0BA8-41FA-A3D0-1B9D6C25C4AA

Q34237413-F6393B75-A798-43C0-99C9-A7A29DC45774

P2860

Q34237413-0A89DB66-59AD-483C-ACC0-B52EDA1AAA75

Q34237413-0E112D66-499B-4CCD-9067-45B696E192A6

Q34237413-2803ACA4-DC97-4864-A144-0E5687F35230

Q34237413-349174F4-E2EC-4AE1-86F2-A71DA8CFD9DD

Q34237413-912BA56C-2844-49D4-9140-F9CF04D15202

Q34237413-E8F9319B-5C38-40DA-9F01-3E7E7D60953A

P304

Q34237413-D95FCCB4-EEDB-43FC-A780-59AD8D9BDDA1

P31

Q34237413-73340751-8B84-477D-BD29-6C0D9E140E53

P356

Q34237413-04F14D6A-7464-4A92-81E5-2CCE97609476

P407

Q34237413-D0262DC0-2B2D-4CB8-914F-3348F5F79F40

P433

Q34237413-F4FA66A5-20CD-4A5C-94B9-DDEC8325FD54

P478

Q34237413-DD953B2F-A977-49B0-901D-9A3228B1F6C3

P50

Q34237413-8BBF42D3-3F3B-413E-8CFE-F374E66118C5

P577

Q34237413-8AF360B0-150A-4526-A6FB-525FBF07A167

P5875

Q34237413-E7CBFFB5-949F-40B4-A35D-D4CC638AC803

P698

Q34237413-8D9CBD28-4ECE-4E52-9BE8-17B880C512D4

P921

Q34237413-93552553-C038-419F-959F-0FFD3357DE55

Q34237413-C7DADB7F-38F7-4C47-898B-2F67722609EF

P932

Q34237413-07C16D02-2415-4A43-92DE-BA516375EECF

P356

P1433

P1476

Initial combination therapy wi ...... patients with type 2 diabetes.

@en

P2093

Craig A Wilson

http://www.w3.org/2001/XMLSchema#string

Jochen Seufert

http://www.w3.org/2001/XMLSchema#string

Penny R Fleck

http://www.w3.org/2001/XMLSchema#string

Qais Mekki

http://www.w3.org/2001/XMLSchema#string

Silvio E Inzucchi

http://www.w3.org/2001/XMLSchema#string

P2860

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus

New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.

Durable efficacy of metformin/glibenclamide combination tablets (Glucovance) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

P304

2406-2408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC10-0159

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Julio Rosenstock

P577

2010-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45721002

http://www.w3.org/2001/XMLSchema#string

P698

20724648

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2963503

http://www.w3.org/2001/XMLSchema#string